OXS 3550Alternative Names: OXIS-3550
Latest Information Update: 22 Sep 2016
At a glance
- Originator University of Minnesota
- Developer Oxis Biotech
- Mechanism of Action CD33 antigen modulators; IgG receptor modulators; Interleukin 15 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical B cell lymphoma